L3VLUP
ProSign in

CHRS · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CHRSGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CHRS
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterCHRSGILD
Q3 20203 holders, $86m25 holders, $14.2bn
Q4 20204 holders, $85m27 holders, $13.4bn
Q1 20213 holders, $3.3m24 holders, $14.5bn
Q2 20213 holders, $3.1m18 holders, $14.9bn
Q3 20211 holders, $26k20 holders, $16.4bn
Q4 20214 holders, $95m20 holders, $16.8bn
Q1 20223 holders, $78m28 holders, $13.2bn
Q2 20221 holders, $10k26 holders, $13.6bn
Q3 20222 holders, $59m24 holders, $13.3bn
Q4 20221 holders, $13k32 holders, $21.1bn
Q1 20232 holders, $778k27 holders, $21.8bn
Q2 20231 holders, $2.1m24 holders, $20.7bn
Q3 20233 holders, $2.2m24 holders, $20.0bn
Q4 20232 holders, $3.6m22 holders, $21.5bn
Q1 20242 holders, $3.0m30 holders, $20.3bn
Q2 20241 holders, $558k28 holders, $18.5bn
Q3 2024none listed holders, n.a.29 holders, $24.2bn
Q4 2024none listed holders, n.a.28 holders, $25.9bn
Q1 2025none listed holders, n.a.33 holders, $32.0bn
Q2 2025none listed holders, n.a.27 holders, $30.9bn
Q3 2025none listed holders, n.a.23 holders, $29.4bn
Q4 2025none listed holders, n.a.25 holders, $34.3bn
Q1 2026none listed holders, n.a.25 holders, $38.5bn
Q2 2026none listed holders, n.a.26 holders, $34.2bn
CHRS

Coherus Oncology Inc

Holders
2
Reported value
$3.0m
Buyers
2
Sellers
0

Breadth +2 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
30
Reported value
$20.3bn
Buyers
17
Sellers
12

Breadth +5 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CHRS (0)

None.

Only GILD (28)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →